Akebia posts Q1 net loss of $9.1M; Vafseo revenue rises to $15.8M, patients up 60%

Akebia Therapeutics, Inc.

2026-Q1 EPS reported -$0.03 revenue$53,544,000

Net loss of $9.1M in Q1 2026 vs net income of $6.1M in Q1 2025; total revenues $53.5M, down from $57.3M.
Vafseo net product revenue $15.8M (+31% YoY); patients on Vafseo increased 60% vs Q4 2025; prescribers up 28%.
Auryxia net revenue $36.2M, down from $43.8M, with generic competition expected to expand in 2026.
Cash $162.6M at March 31, 2026; company expects sufficient cash to fund operations for at least two years.
Pipeline: praliciguat Phase 2 FSGS enrolling; AKB-097 basket study planned H2 2026; AKB-9090 Phase 1 initiated.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Akebia Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: revenue $53.5 million.

Period: the first quarter ended March 31, 2026
Revenue: $53.5 million
Result: reported results

Exact text from the filing

Total revenues were $53.5 million in the first quarter of 2026 compared to $57.3 million in the first quarter of 2025.

View on SEC.gov

Browse all earnings releases →

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001517022-26-000038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.